Michael S. Brown - Mar 29, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Michael S. Brown
Stock symbol
REGN
Transactions as of
Mar 29, 2022
Transactions value $
-$627,018
Form type
4
Date filed
3/31/2022, 04:04 PM
Previous filing
Feb 24, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $569K +1.52K +140.67% $374.12 2.6K Mar 29, 2022 Direct F1
transaction REGN Common Stock Sale -$1.06M -1.52K -58.45% $699.00 1.08K Mar 29, 2022 Direct F1
transaction REGN Common Stock Options Exercise $153K +408 +37.71% $374.12 1.49K Mar 30, 2022 Direct F1
transaction REGN Common Stock Sale -$285K -408 -27.38% $699.00 1.08K Mar 30, 2022 Direct F1
holding REGN Common Stock 5K Mar 29, 2022 by SLAT F2
holding REGN Common Stock 7.16K Mar 29, 2022 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.52K -34.9% $0.00 2.84K Mar 29, 2022 Common Stock 1.52K $374.12 Direct F1, F3
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -408 -14.37% $0.00 2.43K Mar 30, 2022 Common Stock 408 $374.12 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.